Cargando…

Interleukin 6 regulates the expression of programmed cell death ligand 1 in thyroid cancer

Programmed cell death ligand 1 (PD‐L1), inducing T cell exhaustion to facilitate immune escape of tumor cells, is upregulated by interleukin 6 (IL‐6) in T cell lymphoma and ovarian cancer. The purpose of this study is to investigate the expression of IL‐6 and PD‐L1 in thyroid cancer, and whether IL‐...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Guo‐Qiang, Jiao, Qiong, Shen, Chen‐Tian, Song, Hong‐Jun, Zhang, Hui‐Zhen, Qiu, Zhong‐Ling, Luo, Quan‐Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7935800/ https://www.ncbi.nlm.nih.gov/pubmed/33247999 http://dx.doi.org/10.1111/cas.14752

Ejemplares similares

Interleukins in Thyroid Cancer: From Basic Researches to Applications in Clinical Practice
por: Xi, Chuang, et al.
Publicado: (2020)

Programmed death‐ligand 1 expression in swine chronic infections and enhancement of interleukin‐2 production via programmed death‐1/programmed death‐ligand 1 blockade
por: Ganbaatar, Otgontuya, et al.
Publicado: (2021)

Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas
por: Yang, Min-Wei, et al.
Publicado: (2019)

Lung Metastases From Papillary Thyroid Cancer With Persistently Negative Thyroglobulin and Elevated Thyroglobulin Antibody Levels During Radioactive Iodine Treatment and Follow-Up: Long-Term Outcomes and Prognostic Indicators
por: Qiu, Zhong-Ling, et al.
Publicado: (2020)

Transiently impaired endothelial function during thyroid hormone withdrawal in differentiated thyroid cancer patients
por: Hou, Li-ying, et al.
Publicado: (2023)

The Programmed Cell Death Ligand-1/Programmed Cell Death-1 Pathway Mediates Pregnancy-Induced Analgesia via Regulating Spinal Inflammatory Cytokines
por: Tan, HuiLing, et al.
Publicado: (2021)

Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma
por: Nie, Run-Cong, et al.
Publicado: (2020)

Obatoclax and LY3009120 Efficiently Overcome Vemurafenib Resistance in Differentiated Thyroid Cancer
por: Wei, Wei-Jun, et al.
Publicado: (2017)

Interleukin‐17 is associated with expression of programmed cell death 1 ligand 1 in ovarian carcinoma
por: Aotsuka, Aeri, et al.
Publicado: (2019)

Long-Term Outcomes and Prognoses of Elderly Patients (≥65-Years-Old) With Distant Metastases From Well-Differentiated Thyroid Cancer During Radioiodine Therapy and Follow-Up
por: Qiu, Zhong-Ling, et al.
Publicado: (2021)

Association between programmed cell death ligand 1 expression and thyroid cancer: A meta-analysis
por: Wan, Baoyu, et al.
Publicado: (2021)

Association of Programmed Death-Ligand 1 Expression with Aggressive Histological Types of Thyroid Carcinoma
por: Harahap, Agnes Stephanie, et al.
Publicado: (2022)

Change in Antithyroglobulin Antibody Levels is a Good Predictor of Responses to Therapy in Antithyroglobulin Antibody-Positive Pediatric Papillary Thyroid Carcinoma Patients
por: Xi, Chuang, et al.
Publicado: (2022)

Programmed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for Sepsis
por: Liu, Qiang, et al.
Publicado: (2017)

Recent Findings in the Regulation of Programmed Death Ligand 1 Expression
por: Shen, Xiangfeng, et al.
Publicado: (2019)

Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas
por: Zeng, Jing, et al.
Publicado: (2016)

Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
por: Yu, Wei-Bo, et al.
Publicado: (2019)

Non-Apoptotic Programmed Cell Death in Thyroid Diseases
por: Ji, Feihong, et al.
Publicado: (2022)

Prognostic value of programmed cell death ligand-1 expression in breast cancer: A meta-analysis
por: Zhang, Yingzi, et al.
Publicado: (2020)

Programmed Cell Death-1/Programmed Death-Ligand 1 Blockade Improves Survival of Animals with Sepsis: A Systematic Review and Meta-Analysis
por: Zhang, Qiang, et al.
Publicado: (2018)

Diagnostic Performance of (18)F-FDG PET/CT in Papillary Thyroid Carcinoma with Negative (131)I-WBS at first Postablation, Negative Tg and Progressively Increased TgAb Level
por: Qiu, Zhong-Ling, et al.
Publicado: (2017)

Programmed Death-Ligand 1 Expression and Its Correlation with Lymph Node Metastasis in Papillary Thyroid Carcinoma
por: An, Hyo Jung, et al.
Publicado: (2018)

Significance of Interleukin-6 in Papillary Thyroid Carcinoma
por: Kobawala, Toral P., et al.
Publicado: (2016)

Anti-Tumor Potency of Short-Term Interleukin-15 Dendritic Cells Is Potentiated by In Situ Silencing of Programmed-Death Ligands
por: Versteven, Maarten, et al.
Publicado: (2022)

miRNA-106a directly targeting RARB associates with the expression of Na(+)/I(−) symporter in thyroid cancer by regulating MAPK signaling pathway
por: Shen, Chen-Tian, et al.
Publicado: (2016)

Association Between Activation of the Programmed Cell Death-1 (PD-1)/Programmed Death-Ligand 1 (PD-L1) Pathway and Pain in Patients with Cancer
por: Zhang, Jian, et al.
Publicado: (2019)

Strengthening the case that elevated levels of programmed death ligand 1 predict poor prognosis in hepatocellular carcinoma patients
por: Zhong, Jian-Hong, et al.
Publicado: (2016)

Upregulation of programmed death-1 on T cells and programmed death ligand-1 on monocytes in septic shock patients
por: Zhang, Yan, et al.
Publicado: (2011)

Programmed death-ligand 1 expression in the tumour stroma of colorectal liver oligometastases and its association with prognosis after liver resection
por: Peng, Jian-Hong, et al.
Publicado: (2020)

Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants
por: Chowdhury, Subrata, et al.
Publicado: (2016)

The correlation between programmed death-ligand 1 expression and driver gene mutations in NSCLC
por: Yang, Haitao, et al.
Publicado: (2017)

Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis
por: Zhang, Chen, et al.
Publicado: (2021)

Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma
por: Chen, Kaiyan, et al.
Publicado: (2016)

Expression of programmed death ligand-1 predicts poor outcome in nasopharyngeal carcinoma
por: Li, Ying-Fei, et al.
Publicado: (2017)

Improving the synergistic combination of programmed death‐1/programmed death ligand‐1 blockade and radiotherapy by targeting the hypoxic tumour microenvironment
por: Mudassar, Faiqa, et al.
Publicado: (2022)

The relationship between pneumonitis and programmed cell death-1/programmed cell death ligand 1 inhibitors among cancer patients: A systematic review and meta-analysis
por: Xu, Dongmei, et al.
Publicado: (2020)

Effect of baricitinib in regulating programmed death 1 and ligand programmed cell death ligand 1 through JAK/STAT pathway in psoriasis
por: Deepak, H. B., et al.
Publicado: (2022)

Regulation of Neuroinflammation through Programed Death-1/Programed Death Ligand Signaling in Neurological Disorders
por: Zhao, Shangfeng, et al.
Publicado: (2014)

Soluble programmed cell death protein-1 and programmed cell death ligand-1 in sepsis
por: Banerjee, Debasree, et al.
Publicado: (2018)

Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism
por: Jaafar, Jaafar, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_op7ebdgai8neao56lkurnfurs8